Synopsis
Synopsis
0
CEP/COS
0
EU WC
0
KDMF
0
NDC API
0
VMF
DRUG PRODUCT COMPOSITIONS
0
Weekly News Recap #Phispers
1. 28(b)-lys-29(b)-pro-insulin
2. 28(b)-lysine-29(b)-prolineinsulin
3. Humalog
4. Humalog Kwikpen
5. Insulin, Lys(28b)-pro(29b)-
6. Insulin, Lysyl(28b)-prolyl(28b)-
7. Kwikpen, Humalog
8. Lispro
9. Lispro, Insulin
10. Lyspro
1. 133107-64-9
2. Insulin Lispro (5.97 Mg)
3. Insulin-lispro
4. Dtxsid90157956
Molecular Weight | 5814 g/mol |
---|---|
Molecular Formula | C257H389N65O77S6 |
Hydrogen Bond Donor Count | 84 |
Hydrogen Bond Acceptor Count | 89 |
Rotatable Bond Count | 185 |
Exact Mass | 5811.6913101 g/mol |
Monoisotopic Mass | 5809.6846004 g/mol |
Topological Polar Surface Area | 2310 Ų |
Heavy Atom Count | 405 |
Formal Charge | 0 |
Complexity | 13000 |
Isotope Atom Count | 0 |
Defined Atom Stereocenter Count | 52 |
Undefined Atom Stereocenter Count | 0 |
Defined Bond Stereocenter Count | 0 |
Undefined Bond Stereocenter Count | 0 |
Covalently Bonded Unit Count | 2 |
1 of 2 | |
---|---|
Drug Name | Humalog |
PubMed Health | Insulin Lispro |
Drug Classes | Antidiabetic |
Drug Label | Humalog Mix50/50 [50% insulin lispro protamine suspension and 50% insulin lispro injection, (rDNA origin)] is a mixture of insulin lispro solution, a rapid-acting blood glucose-lowering agent and insulin lispro protamine suspension, an intermedi... |
Active Ingredient | Insulin lispro recombinant |
Dosage Form | Injectable |
Route | Injection |
Strength | 100 units/ml |
Market Status | Prescription |
Company | Lilly |
2 of 2 | |
---|---|
Drug Name | Humalog |
PubMed Health | Insulin Lispro |
Drug Classes | Antidiabetic |
Drug Label | Humalog Mix50/50 [50% insulin lispro protamine suspension and 50% insulin lispro injection, (rDNA origin)] is a mixture of insulin lispro solution, a rapid-acting blood glucose-lowering agent and insulin lispro protamine suspension, an intermedi... |
Active Ingredient | Insulin lispro recombinant |
Dosage Form | Injectable |
Route | Injection |
Strength | 100 units/ml |
Market Status | Prescription |
Company | Lilly |
Insulin lispro is indicated to improve glycemic control in adults and children with diabetes mellitus.
FDA Label
Treatment of diabetes mellitus in adults.
For the treatment of adults and children with diabetes mellitus who require insulin for the maintenance of normal glucose homeostasis. Insulin lispro Sanofi is also indicated for the initial stabilisation of diabetes mellitus.
For the treatment of adults and children with diabetes mellitus who require insulin for the maintenance of normal glucose homeostasis. Liprolog is also indicated for the initial stabilisation of diabetes mellitus.
For the treatment of adults and children with diabetes mellitus who require insulin for the maintenance of normal glucose homeostasis. Humalog is also indicated for the initial stabilisation of diabetes mellitus.
For the treatment of patients with diabetes mellitus who require insulin for the maintenance of normal glucose homeostasis. Liprolog is also indicated for the initial stabilization of diabetes mellitus. Liprolog is a short acting insulin and may be used in conjunction with a longer acting human insulin. Liprolog is indicated for preprandial administration.
Insulin is a natural hormone produced by beta cells of the pancreas. In non-diabetic individuals, a basal level of insulin is supplemented with insulin spikes following meals. Increased insulin secretion following meals is responsible for the metabolic changes that occur as the body transitions from a postabsorptive to absorptive state. Insulin promotes cellular uptake of glucose, particularly in muscle and adipose tissues, promotes energy storage via glycogenesis, opposes catabolism of energy stores, increases DNA replication and protein synthesis by stimulating amino acid uptake by liver, muscle and adipose tissue, and modifies the activity of numerous enzymes involved in glycogen synthesis and glycolysis. Insulin also promotes growth and is required for the actions of growth hormone (e.g. protein synthesis, cell division, DNA synthesis). Insulin lispro is a rapid-acting insulin analogue used to mimic postprandial insulin spikes in diabetic individuals. The onset of action of insulin lispro is 10-15 minutes. Its activity peaks 60 minutes following subcutaneous injection and its duration of action is 4-5 hours. Compared to regular human insulin, insulin lispro has a more rapid onset of action and a shorter duration of action. Insulin lispro is also shown to be equipotent to human insulin on a molar basis.
Hypoglycemic Agents
Substances which lower blood glucose levels. (See all compounds classified as Hypoglycemic Agents.)
A10AB04
A10AB04
A10AB04, A10AD04
A10AB04, A10AD04
A10AB04
A - Alimentary tract and metabolism
A10 - Drugs used in diabetes
A10A - Insulins and analogues
A10AB - Insulins and analogues for injection, fast-acting
A10AB04 - Insulin lispro
A - Alimentary tract and metabolism
A10 - Drugs used in diabetes
A10A - Insulins and analogues
A10AC - Insulins and analogues for injection, intermediate-acting
A10AC04 - Insulin lispro
A - Alimentary tract and metabolism
A10 - Drugs used in diabetes
A10A - Insulins and analogues
A10AD - Insulins and analogues for injection, intermediate- or long-acting combined with fast-acting
A10AD04 - Insulin lispro
Absorption
Insulin lispro is rapidly absorbed following subcutaneous administration. It is also absorbed more quickly than regular human insulin. Peak serum levels occur 30-90 minutes after injection in healthy subjects. Absorption also differs depending on the site of injection. After insulin lispro was administered in the abdomen, serum drug levels were higher and the duration of action was slightly shorter than after deltoid or thigh administration. The absolute bioavailability after subcutaneous injection ranges from 55% to 77% with doses between 0.1 to 0.2 unit/kg, inclusive. The mean observed area under the serum insulin concentration-time curve from time zero to infinity was 2360 pmol hr/L and 2390 pmol hr/L for HUMALOG U-200 and HUMALOG U-100, respectively. The corresponding mean peak serum insulin concentration was 795 pmol/L and 909 pmol/L for HUMALOG U-200 and HUMALOG U-100, respectively. The median time to maximum concentration was 1.0 hour for both formulations.
Volume of Distribution
When administered intravenously as bolus injections of 0.1 and 0.2 U/kg dose in two separate groups of healthy subjects, the mean volume of distribution of insulin lispro appeared to decrease with increase in dose (1.55 and 0.72 L/kg, respectively).
Clearance
Clearance is dose dependent. When a dose of 0.1 unit/kg and 0.2 unit/kg were administered intravenously, the mean clearance was 21.0 mL/min/kg and 9.6 mL/min/kg respectively.
Insulin is predominantly cleared by metabolic degradation via a receptor-mediated process.
After subcutaneous administration of insulin lispro, the t1/2 is shorter than that of regular human insulin (1 versus 1.5 hours, respectively).
Insulin lispro binds to the insulin receptor (IR), a heterotetrameric protein consisting of two extracellular alpha units and two transmembrane beta units. The binding of insulin to the alpha subunit of IR stimulates the tyrosine kinase activity intrinsic to the beta subunit of the receptor. The bound receptor autophosphorylates and phosphorylates numerous intracellular substrates such as insulin receptor substrates (IRS) proteins, Cbl, APS, Shc and Gab 1. Activation of these proteins leads to the activation of downstream signaling molecules including PI3 kinase and Akt. Akt regulates the activity of glucose transporter 4 (GLUT4) and protein kinase C (PKC), both of which play critical roles in metabolism and catabolism. In humans, insulin is stored in the form of hexamers; however, only insulin monomers are able to interact with IR. Reversal of the proline and lysine residues at positions B28 and B29 of native insulin eliminates hydrophobic interactions and weakens some of the hydrogen bonds that contribute to the stability of the insulin dimers that comprise insulin hexamers. Hexamers of insulin lispro are produced in the presence of zinc and m-cresol. These weakly associated hexamers quickly dissociate upon subcutaneous injection and are absorbed as monomers through vascular endothelial cells. These properties give insulin lispro its fast-acting properties.
Sanofi is a pioneer in Diabetes Solutions, Human Vaccines, Innovative Drugs, Consumer Healthcare, and the new Genzyme.
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 4846
Submission : 1983-03-11
Status : Inactive
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 23892
Submission : 2010-06-07
Status : Active
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 5527
Submission : 1984-09-14
Status : Inactive
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 5533
Submission : 1984-09-14
Status : Inactive
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 17123
Submission : 2004-01-27
Status : Inactive
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 27702
Submission : 2013-11-28
Status : Inactive
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 32125
Submission : 2017-12-01
Status : Inactive
Type : II
Registration Number : 217MF10534
Registrant's Address : Lilly Corporate Center, Indianapolis, Indiana 46285, USA
Initial Date of Registration : 2005-09-09
Latest Date of Registration :
Registration Number : 219MF10053
Registrant's Address : 65th Infantry Road, Km. 12.6, Carolina, Puerto Rico 00985
Initial Date of Registration : 2007-03-05
Latest Date of Registration :
Sanofi is a pioneer in Diabetes Solutions, Human Vaccines, Innovative Drugs, Consumer Healthcare, and the new Genzyme.
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 4846
Submission : 1983-03-11
Status : Inactive
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 23892
Submission : 2010-06-07
Status : Active
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 17123
Submission : 2004-01-27
Status : Inactive
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 32125
Submission : 2017-12-01
Status : Inactive
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 27702
Submission : 2013-11-28
Status : Inactive
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 5533
Submission : 1984-09-14
Status : Inactive
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 5527
Submission : 1984-09-14
Status : Inactive
Type : II
Insulin Lispro (genetical recombination)
Registration Number : 303MF10175
Registrant's Address : 65th Infantry Road, Km. 12.6, Carolina, Puerto Rico 00985
Initial Date of Registration : 2021-12-09
Latest Date of Registration : 2021-12-09
Insulin Lispro (genetical recombination)
Registration Number : 226MF10225
Registrant's Address : Lilly Corporate Center, Indianapolis, Indiana 46285, USA
Initial Date of Registration : 2014-12-08
Latest Date of Registration : 2017-12-25
Insulin Lispro (genetical recombination)
Registration Number : 217MF10534
Registrant's Address : Lilly Corporate Center, Indianapolis, Indiana 46285, USA
Initial Date of Registration : 2005-09-09
Latest Date of Registration : 2017-12-25
Insulin Lispro (genetical recombination)
Registration Number : 229MF10064
Registrant's Address : 65th Infantry Road, Km. 12.6, Carolina, Puerto Rico 00985
Initial Date of Registration : 2017-03-13
Latest Date of Registration : 2017-12-25
Insulin Lispro (genetical recombination)
Registration Number : 219MF10053
Registrant's Address : 65th Infantry Road, Km. 12.6, Carolina, Puerto Rico 00985
Initial Date of Registration : 2007-03-05
Latest Date of Registration : 2017-12-25
About the Company : Wanbang Biopharmaceuticals is a leading anti-diabetic pharmaceutical company in China and a core member of Fosun Group (SH600196; HK02196). Wanbang Biopharma has been focusing at t...
Details:
Through the acquisition, Lupin will enhance its portfolio and gain the right to commercialize Humulin N (human insulin) in India. It is indicated for the treatment of diabetes mellitus.
Lead Product(s): Insulin Lispro
Therapeutic Area: Endocrinology Brand Name: Undisclosed
Study Phase: ApprovedProduct Type: Peptide
Sponsor: Lupin Ltd
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Acquisition December 30, 2024
Lead Product(s) : Insulin Lispro
Therapeutic Area : Endocrinology
Highest Development Status : Approved
Partner/Sponsor/Collaborator : Lupin Ltd
Deal Size : Undisclosed
Deal Type : Acquisition
Lupin Acquires Huminsulin from Lilly, Enhance Diabetes Portfolio
Details : Through the acquisition, Lupin will enhance its portfolio and gain the right to commercialize Humulin N (human insulin) in India. It is indicated for the treatment of diabetes mellitus.
Product Name : Undisclosed
Product Type : Peptide
Upfront Cash : Undisclosed
December 30, 2024
Details:
Afrezza (human Insulin) is the only ultra rapid-acting inhaled insulin that act as Insulin receptor agonist, which is investigated in combination with insulin degludec for the treatment of type 1 diabetes.
Lead Product(s): Insulin Lispro
Therapeutic Area: Endocrinology Brand Name: Afrezza
Study Phase: Phase IVProduct Type: Peptide
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 06, 2023
Lead Product(s) : Insulin Lispro
Therapeutic Area : Endocrinology
Highest Development Status : Phase IV
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : Afrezza (human Insulin) is the only ultra rapid-acting inhaled insulin that act as Insulin receptor agonist, which is investigated in combination with insulin degludec for the treatment of type 1 diabetes.
Product Name : Afrezza
Product Type : Peptide
Upfront Cash : Not Applicable
November 06, 2023
Details:
Through the acquisition, Lilly will gain control of the partnered encapsulated cell therapies, including SIG-002 (human insulin), for the treatment of type 1 diabetes.
Lead Product(s): Insulin Lispro
Therapeutic Area: Endocrinology Brand Name: SIG-002
Study Phase: DiscoveryProduct Type: Peptide
Sponsor: Eli Lilly
Deal Size: $344.2 million Upfront Cash: $344.2 million
Deal Type: Acquisition June 29, 2023
Lead Product(s) : Insulin Lispro
Therapeutic Area : Endocrinology
Highest Development Status : Discovery
Partner/Sponsor/Collaborator : Eli Lilly
Deal Size : $344.2 million
Deal Type : Acquisition
Lilly to Acquire Sigilon Therapeutics
Details : Through the acquisition, Lilly will gain control of the partnered encapsulated cell therapies, including SIG-002 (human insulin), for the treatment of type 1 diabetes.
Product Name : SIG-002
Product Type : Peptide
Upfront Cash : $344.2 million
June 29, 2023
Details:
Afrezza (human insulin) is the only ultra rapid-acting inhaled insulin that act as Insulin receptor agonist and works as starts lowering blood sugars in ~12 minutes for adults living with type 1 or type 2 diabetes.
Lead Product(s): Insulin Lispro
Therapeutic Area: Endocrinology Brand Name: Afrezza
Study Phase: Phase IVProduct Type: Peptide
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 22, 2023
Lead Product(s) : Insulin Lispro
Therapeutic Area : Endocrinology
Highest Development Status : Phase IV
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : Afrezza (human insulin) is the only ultra rapid-acting inhaled insulin that act as Insulin receptor agonist and works as starts lowering blood sugars in ~12 minutes for adults living with type 1 or type 2 diabetes.
Product Name : Afrezza
Product Type : Peptide
Upfront Cash : Not Applicable
June 22, 2023
Details:
Inpremzia is an approved medicine used to treat people with diabetes who need insulin to keep their blood glucose (sugar) level controlled. It contains the active substance insulin human.
Lead Product(s): Insulin Lispro
Therapeutic Area: Endocrinology Brand Name: Inpremzia
Study Phase: ApprovedProduct Type: Peptide
Sponsor: Biocon
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 25, 2022
Lead Product(s) : Insulin Lispro
Therapeutic Area : Endocrinology
Highest Development Status : Approved
Partner/Sponsor/Collaborator : Biocon
Deal Size : Not Applicable
Deal Type : Not Applicable
Biocon Biologics’ Partner Receives Approval for Human Insulin for IV Infusion
Details : Inpremzia is an approved medicine used to treat people with diabetes who need insulin to keep their blood glucose (sugar) level controlled. It contains the active substance insulin human.
Product Name : Inpremzia
Product Type : Peptide
Upfront Cash : Not Applicable
April 25, 2022
Details:
The primary objective of Phase 3 program is to demonstrate non-inferiority of BC Lispro on HbA1c reduction from baseline vs. Humalog. BioChaperone® Lispro (BC Lispro) is ultra-rapid prandial insulin containing insulin lispro and Adocia’s proprietary technology BioChaperone®.
Lead Product(s): Insulin Lispro
Therapeutic Area: Endocrinology Brand Name: BioChaperone Lispro
Study Phase: Phase IProduct Type: Peptide
Sponsor: Adocia
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 14, 2021
Lead Product(s) : Insulin Lispro
Therapeutic Area : Endocrinology
Highest Development Status : Phase I
Partner/Sponsor/Collaborator : Adocia
Deal Size : Not Applicable
Deal Type : Not Applicable
Adocia’s partner Tonghua Dongbao Receives Clearance to Start Ultra-Rapid Insulin BioChaperone® ...
Details : The primary objective of Phase 3 program is to demonstrate non-inferiority of BC Lispro on HbA1c reduction from baseline vs. Humalog. BioChaperone® Lispro (BC Lispro) is ultra-rapid prandial insulin containing insulin lispro and Adocia’s proprietary t...
Product Name : BioChaperone Lispro
Product Type : Peptide
Upfront Cash : Not Applicable
October 14, 2021
Details:
As a part of this agreement, Lilly will transfer its rights in India to sell, promote and distribute the aforesaid two Lilly Diabetes products – Humalog® & TrulicityTM to Cipla, subject to all regulatory approvals.
Lead Product(s): Insulin Lispro
Therapeutic Area: Endocrinology Brand Name: Humalog
Study Phase: ApprovedProduct Type: Peptide
Sponsor: Eli Lilly
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Partnership October 04, 2021
Lead Product(s) : Insulin Lispro
Therapeutic Area : Endocrinology
Highest Development Status : Approved
Partner/Sponsor/Collaborator : Eli Lilly
Deal Size : Undisclosed
Deal Type : Partnership
Cipla to sell Eli Lilly's Insulin Products Humalog, Trulicity in India
Details : As a part of this agreement, Lilly will transfer its rights in India to sell, promote and distribute the aforesaid two Lilly Diabetes products – Humalog® & TrulicityTM to Cipla, subject to all regulatory approvals.
Product Name : Humalog
Product Type : Peptide
Upfront Cash : Undisclosed
October 04, 2021
Details:
Pramlintide, despite being the only drug approved as an adjunct to insulin in type 1 diabetes, is underused as it requires three additional daily injections in addition to the multiple injections of insulin.
Lead Product(s): Insulin Lispro,Pramlintide
Therapeutic Area: Endocrinology Brand Name: BC LisPram
Study Phase: Phase IProduct Type: Peptide
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 29, 2021
Lead Product(s) : Insulin Lispro,Pramlintide
Therapeutic Area : Endocrinology
Highest Development Status : Phase I
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Adocia Initiates BC LisPram Phase 1 Clinical Trial in Pump for People with Type 1 Diabetes
Details : Pramlintide, despite being the only drug approved as an adjunct to insulin in type 1 diabetes, is underused as it requires three additional daily injections in addition to the multiple injections of insulin.
Product Name : BC LisPram
Product Type : Peptide
Upfront Cash : Not Applicable
June 29, 2021
Details:
The purpose of the study is to confirm and optimize the safety and efficacy of M1Pram in comparison with insulin lispro (Humalog®, Eli Lilly) in regard to glycemic control and body weight reduction.
Lead Product(s): Insulin Lispro
Therapeutic Area: Endocrinology Brand Name: M1 Pram P037
Study Phase: Phase IIProduct Type: Peptide
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 10, 2021
Lead Product(s) : Insulin Lispro
Therapeutic Area : Endocrinology
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Adocia Initiates Phase 2 Clinical Trial for M1Pram in Patients with Type 1 Diabetes
Details : The purpose of the study is to confirm and optimize the safety and efficacy of M1Pram in comparison with insulin lispro (Humalog®, Eli Lilly) in regard to glycemic control and body weight reduction.
Product Name : M1 Pram P037
Product Type : Peptide
Upfront Cash : Not Applicable
March 10, 2021
Details:
Companies will partner to promote Lyumjev, Lilly's new rapid-acting insulin, with Dexcom G6 Continuous Glucose Monitoring (CGM), highlighting the benefits of using each.
Lead Product(s): Insulin Lispro
Therapeutic Area: Endocrinology Brand Name: Lyumjev
Study Phase: ApprovedProduct Type: Peptide
Sponsor: Eli Lilly
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Partnership October 07, 2020
Lead Product(s) : Insulin Lispro
Therapeutic Area : Endocrinology
Highest Development Status : Approved
Partner/Sponsor/Collaborator : Eli Lilly
Deal Size : Undisclosed
Deal Type : Partnership
Lilly and Dexcom Team Up on New Program to Help Improve Diabetes Management
Details : Companies will partner to promote Lyumjev, Lilly's new rapid-acting insulin, with Dexcom G6 Continuous Glucose Monitoring (CGM), highlighting the benefits of using each.
Product Name : Lyumjev
Product Type : Peptide
Upfront Cash : Undisclosed
October 07, 2020
Related Excipient Companies
Dosage Form : Tablet
Grade : Oral
Dosage Form : Cream / Lotion / Ointment
Grade : Topical, Parenteral
Excipients by Applications
Global Sales Information
Market Place
Patents & EXCLUSIVITIES
REF. STANDARDS & IMPURITIES
ABOUT THIS PAGE
36
PharmaCompass offers a list of Insulin Lispro API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, Price,and more, enabling you to easily find the right Insulin Lispro manufacturer or Insulin Lispro supplier for your needs.
Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Insulin Lispro manufacturer or Insulin Lispro supplier.
PharmaCompass also assists you with knowing the Insulin Lispro API Price utilized in the formulation of products. Insulin Lispro API Price is not always fixed or binding as the Insulin Lispro Price is obtained through a variety of data sources. The Insulin Lispro Price can also vary due to multiple factors, including market conditions, regulatory modifications, or negotiated pricing deals.
A Insulin Lispro manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Insulin Lispro, including repackagers and relabelers. The FDA regulates Insulin Lispro manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Insulin Lispro API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of Insulin Lispro manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A Insulin Lispro supplier is an individual or a company that provides Insulin Lispro active pharmaceutical ingredient (API) or Insulin Lispro finished formulations upon request. The Insulin Lispro suppliers may include Insulin Lispro API manufacturers, exporters, distributors and traders.
click here to find a list of Insulin Lispro suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
A Insulin Lispro DMF (Drug Master File) is a document detailing the whole manufacturing process of Insulin Lispro active pharmaceutical ingredient (API) in detail. Different forms of Insulin Lispro DMFs exist exist since differing nations have different regulations, such as Insulin Lispro USDMF, ASMF (EDMF), JDMF, CDMF, etc.
A Insulin Lispro DMF submitted to regulatory agencies in the US is known as a USDMF. Insulin Lispro USDMF includes data on Insulin Lispro's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The Insulin Lispro USDMF is kept confidential to protect the manufacturer’s intellectual property.
click here to find a list of Insulin Lispro suppliers with USDMF on PharmaCompass.
The Pharmaceuticals and Medical Devices Agency (PMDA) established the Japan Drug Master File (JDMF), also known as the Master File (MF), to permit Japanese and foreign manufacturers of drug substances, intermediates, excipients, raw materials, and packaging materials (‘Products’) to voluntarily register confidential information about the production and management of their products in Japan.
The Insulin Lispro Drug Master File in Japan (Insulin Lispro JDMF) empowers Insulin Lispro API manufacturers to present comprehensive information (e.g., production methods, data, etc.) to the review authority, i.e., PMDA (Pharmaceuticals & Medical Devices Agency).
PMDA reviews the Insulin Lispro JDMF during the approval evaluation for pharmaceutical products. At the time of Insulin Lispro JDMF registration, PMDA checks if the format is accurate, if the necessary items have been included (application), and if data has been attached.
click here to find a list of Insulin Lispro suppliers with JDMF on PharmaCompass.
Insulin Lispro Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Insulin Lispro GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Insulin Lispro GMP manufacturer or Insulin Lispro GMP API supplier for your needs.
A Insulin Lispro CoA (Certificate of Analysis) is a formal document that attests to Insulin Lispro's compliance with Insulin Lispro specifications and serves as a tool for batch-level quality control.
Insulin Lispro CoA mostly includes findings from lab analyses of a specific batch. For each Insulin Lispro CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Insulin Lispro may be tested according to a variety of international standards, such as European Pharmacopoeia (Insulin Lispro EP), Insulin Lispro JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Insulin Lispro USP).